ChineseInvestors.com, Inc. (CIIX) Covered in New R
Post# of 346
(Total Views: 162)
Posted On: 01/23/2017 4:43:44 PM
ChineseInvestors.com, Inc. (CIIX) Covered in New Report from WallStreet Research™
Before the opening bell, top-ranked independent research firm WallStreet Research™ (WSR) announced the release of a Corporate Profile Analyst Report covering ChineseInvestors.com, Inc. (OTCQB: CIIX). In addition to highlighting CIIX’s ongoing operations, including both its efforts to provide a range of financial information to the global Chinese population via www.Chinesefn.com and its preparations to capitalize on the thriving market for cannabidiol-based products through its www.ChineseCBDoil.com website, the WSR report gives prospective investors some additional insight into the tremendous growth opportunities presented by the company’s evolving strategy.
“The Company’s recent announcements regarding expansion into the medical marijuana and CBD oil industry has driven great interest in CIIX shares,” Alan Stone, managing director of WSR, stated in this morning’s news release. “As a result, the shares have significantly increased in both market value and trading volume, potentially positioning the company for a listing either on the NASDAQ or the NYSE Markets sometime later in 2017.”
In recent weeks, CIIX has made considerable progress toward the impending launch of its operations in the emerging global cannabis industry. Last month, the company announced a new partnership with a well-known cannabidiol (CBD) health brand that will enable CIIX to retail nutritional supplements containing CBD to the Asian market through both online and in-store distribution channels. Shortly after that announcement, CIIX unveiled plans to launch the world’s first CBD health products online store available in the Chinese language by the end of January 2017. The headquarters for this operation will be located in Shanghai, and the company has already outlined plans to create a wholly-owned subsidiary within the Shanghai Free Trade Zone with the sole focus of supplying CBD-based health products to the expansive worldwide Chinese population.
This morning’s release of a research report from WSR came just days after the release of a similar update from Traders News Source (TNS), an equity research firm specializing in small and micro-cap securities. The TNS report also placed a great deal of focus on CIIX’s recent entry into the cannabis industry through www.ChineseCBDoil.com. The firm notes that, while marijuana use is currently illegal in the People’s Republic of China, cannabis-based oils are legal, providing a potential market for CIIX that includes well over one billion people in China alone.
For more information, visit www.ChineseInvestors.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
Before the opening bell, top-ranked independent research firm WallStreet Research™ (WSR) announced the release of a Corporate Profile Analyst Report covering ChineseInvestors.com, Inc. (OTCQB: CIIX). In addition to highlighting CIIX’s ongoing operations, including both its efforts to provide a range of financial information to the global Chinese population via www.Chinesefn.com and its preparations to capitalize on the thriving market for cannabidiol-based products through its www.ChineseCBDoil.com website, the WSR report gives prospective investors some additional insight into the tremendous growth opportunities presented by the company’s evolving strategy.
“The Company’s recent announcements regarding expansion into the medical marijuana and CBD oil industry has driven great interest in CIIX shares,” Alan Stone, managing director of WSR, stated in this morning’s news release. “As a result, the shares have significantly increased in both market value and trading volume, potentially positioning the company for a listing either on the NASDAQ or the NYSE Markets sometime later in 2017.”
In recent weeks, CIIX has made considerable progress toward the impending launch of its operations in the emerging global cannabis industry. Last month, the company announced a new partnership with a well-known cannabidiol (CBD) health brand that will enable CIIX to retail nutritional supplements containing CBD to the Asian market through both online and in-store distribution channels. Shortly after that announcement, CIIX unveiled plans to launch the world’s first CBD health products online store available in the Chinese language by the end of January 2017. The headquarters for this operation will be located in Shanghai, and the company has already outlined plans to create a wholly-owned subsidiary within the Shanghai Free Trade Zone with the sole focus of supplying CBD-based health products to the expansive worldwide Chinese population.
This morning’s release of a research report from WSR came just days after the release of a similar update from Traders News Source (TNS), an equity research firm specializing in small and micro-cap securities. The TNS report also placed a great deal of focus on CIIX’s recent entry into the cannabis industry through www.ChineseCBDoil.com. The firm notes that, while marijuana use is currently illegal in the People’s Republic of China, cannabis-based oils are legal, providing a potential market for CIIX that includes well over one billion people in China alone.
For more information, visit www.ChineseInvestors.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
(0)
(0)